keyword
MENU ▼
Read by QxMD icon Read
search

dlqi

keyword
https://www.readbyqxmd.com/read/28314658/management-of-chronic-inducible-urticaria-according-to-the-guidelines-a-prospective-controlled-study
#1
Emek Kocatürk, Pelin Kuteyla Can, Pırıl Etikan Akbas, Mehmet Copur, Ece Nur Degirmentepe, Kübra Kızıltac, Ralfi Singer
BACKGROUND: The recommended treatment approach in chronic inducible urticarias (CIndU) is the same as that for chronic spontaneous urticaria (CSU). But there is a lack of controlled trials assessing efficacy of available treatment options. OBJECTIVE: We aimed to evaluate the efficacy of treatment algorithm recommended by the guidelines and comparison of treatment responses in CIndU vs CSU. METHODS: This prospective parallel group controlled study included 70 CIndU and 66 CSU patients...
March 1, 2017: Journal of Dermatological Science
https://www.readbyqxmd.com/read/28301043/a-topical-treatment-optimisation-programme-ttop-improves-clinical-outcome-to-calcipotriol-betamethasone-gel-in-psoriasis-results-of-the-64-week-multinational-randomized-phase-iv-study-in-1790-patients-pso-top
#2
K Reich, I Zschocke, H Bachelez, E M G J de Jong, P Gisondi, L Puig, R B Warren, C Ortland, U Mrowietz
BACKGROUND: Around two-thirds of psoriasis patients do not adhere to topical treatment. The 'Topical Treatment Optimisation Programme' (TTOP), a five-element tool, includes guidance for the conversation between dermatologists/nurses and patients, patient information material, telephone/email helpdesks and treatment reminders. It has been developed by patients and dermatologists to help increase adherence in psoriasis. OBJECTIVE: To compare TTOP with standard of care ('non-TTOP') within a large European investigator-initiated study, PSO-TOP (Clinicaltrials...
March 16, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28300857/evaluation-of-the-physician-global-assessment-and-body-surface-area-composite-tool-for-assessing-psoriasis-response-to-apremilast-therapy-results-from-esteem-1-and-esteem-2
#3
Kristina C Duffin, Kim A Papp, Jerry Bagel, Eugenia Levi, Rongdean Chen, Alice B Gottlieb
BACKGROUND: The Physician Global Assessment and Body Surface Area (PGAxBSA) composite tool is a simple, effective alternative for measuring psoriasis severity. OBJECTIVE: To evaluate the product of PGAxBSA as a sensitive alternative to the Psoriasis Area and Severity Index (PASI) for assessing disease severity and therapeutic response with data collected from the phase 3 ESTEEM 1 and 2 trials. METHODS: This post hoc analysis included 836 patients randomized to apremilast 30 mg BID at baseline (ESTEEM 1, n=562; ESTEEM 2, n=274)...
February 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28295198/analysis-of-disease-activity-categories-in-chronic-spontaneous-idiopathic-urticaria
#4
D Stull, D McBride, H Tian, A Gimenez Arnau, M Maurer, A Marsland, M-M Balp, S Khalil, C Grattan
BACKGROUND: Measurement of disease activity guides treatment of chronic spontaneous urticaria (CSU). A weekly Urticaria Activity Score-here, the average of twice-daily patient assessment of itch and hives scores summed over 1 week (UAS7TD )-measures severity from 0 to 42. Insufficient evidence exists whether disease activity states, defined by categorical UAS7TD scores, correlate with other patient-reported outcomes and treatment response. OBJECTIVE: To evaluate and compare categorical UAS7TD scores with selected measures of disease-related quality of life and impact...
March 13, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28294430/rapid-improvements-in-health-related-quality-of-life-and-itch-with-ixekizumab-treatment-in-randomized-phase-3-trials-results-from-uncover-2-and-uncover-3
#5
C L Leonardi, A Blauvelt, H L Sofen, M Gooderham, M Augustin, R Burge, B Zhu, K Reich
BACKGROUND: Patients with moderate-to-severe psoriasis report impaired health-related quality of life (HRQoL). OBJECTIVE: To assess speed of onset of ixekizumab-induced clinically relevant improvement in HRQoL. METHODS: This post-hoc analysis used pooled data from patients randomized in UNCOVER-2 and UNCOVER-3, and treated with 80 mg ixekizumab every 2 weeks (IXEQ2W), 80 mg ixekizumab every 4 weeks (IXEQ4W), 50 mg etanercept (ETN) twice weekly, or placebo (PBO) for 12 weeks...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28294420/chronic-urticaria-in-the-real-life-clinical-practice-setting-in-sweden-norway-and-denmark-baseline-results-from-the-non-interventional-multicentre-aware-study
#6
S F Thomsen, E C Pritzier, C D Anderson, N Vaugelade-Baust, R Dodge, A-K Dahlborn, C Vestergaard
BACKGROUND: Chronic urticaria (CU) is characterised by the recurrence of itchy hives and/or angioedema for more than six weeks. AWARE (A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation) is a multinational study designed to document the real-life treatment situation, burden of disease, and clinical resource usage of H1-antihistamine refractory CU patients. OBJECTIVE: To examine baseline data from Scandinavian AWARE patients. METHODS: AWARE is a prospective, non-interventional, multinational, umbrella design study, which includes adults (≥18 years) with a confirmed CU diagnosis (>2 months) that is refractory to H1-antihistamines...
March 10, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28271561/a-european-subset-analysis-from-the-population-based-multinational-assessment-of-psoriasis-and-psoriatic-arthritis-mapp-shows-country-specific-features-results-from-psoriasis-patients-in-spain
#7
L Puig, P C M van de Kerkhof, K Reich, H Bachelez, J Barker, G Girolomoni, C F Paul
BACKGROUND: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC). OBJECTIVE: Utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI). METHODS: MAPP was conducted between June and August 2012. This analysis included 1700 patients with self-reported psoriasis (without psoriatic arthritis) from France (n=349), Germany (n=311), Italy (n=359), Spain (n=354) and the United Kingdom (n=327)...
March 8, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28266243/psoriasis-patients-with-psoriasis-area-and-severity-index-pasi-90-response-achieve-greater-health-related-quality-of-life-improvements-than-those-with-pasi-75-89-response-results-from-two-phase-3-studies-of-secukinumab
#8
Boni E Elewski, Lluís Puig, Margaret Mordin, Isabelle Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, Charis Papavassilis, Bruce E Strober
BACKGROUND: The emergence of new biological therapies showing high and sustained level of Psoriasis Area and Severity Index (PASI) 90 response has provided the possibility of both greater skin clearance and increased quality of life (QOL). OBJECTIVE: To evaluate the association of greater response in skin clearance with improvements in skin-related QOL up to 52 weeks. METHODS: Subjects achieving various levels of skin clearance (PASI 90-100 or PASI 75-89) and Dermatology Life Quality Index (DLQI) (0/1) response were compared using ERASURE and FIXTURE trial data...
March 7, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28252813/quality-of-life-and-comorbidities-in-palmoplantar-pustulosis-a-cross-sectional-study-on-102-patients
#9
H Trattner, S Blüml, I Steiner, U Plut, S Radakovic, A Tanew
BACKGROUND: Association of palmoplantar pustulosis (PPP) with metabolic and autoimmune diseases has been reported in mostly small case series or anecdotal cases. OBJECTIVE: To assess health-related quality of life and prevalence of comorbidities in a large cohort of PPP patients. METHODS: We conducted a cross-sectional study on patients with either active or past PPP. Disease severity was measured by the Palmoplantar Pustulosis Area and Severity Index (ppPASI)...
March 2, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28214318/clinical-course-treatment-modalities-and-quality-of-life-in-patients-with-congenital-melanocytic-nevi-data-from-the-german-cmn-registry
#10
Maria Elisabeth Wramp, Anna Langenbruch, Matthias Augustin, Detlef Zillikens, Sven Krengel
BACKGROUND: Congenital melanocytic nevi (CMN) are associated with mental stress as well as medical risks for those affected. The German CMN registry was initiated in 2005. Herein, we present results from an interim analysis focusing on disease course, treatment modalities, and quality of life. PATIENTS AND METHODS: One hundred patients enrolled in the registry between 2005 and 2012 were included in this prospective cohort study, and asked to participate in a follow-up survey...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214309/wirksamkeit-und-sicherheit-von-fumars%C3%A3-ureestern-in-kombination-mit-phototherapie-bei-patienten-mit-moderater-bis-schwerer-plaque-psoriasis-fast
#11
Peter Weisenseel, Kristian Reich, Wiebke Griemberg, Katharina Merten, Christine Gröschel, Natalie Nunez Gomez, Kirsi Taipale, Beate Bräu, Ina Zschocke
HINTERGRUND: Die Behandlung von Psoriasis-Patienten mit einer Kombination aus Fumarsäureestern (FSE, Fumaderm(®) ) und Phototherapie (UV) ist verbreitet, wurde aber im Rahmen von Studien wenig untersucht. Bisher liegen lediglich Daten aus einer kleinen Pilotstudie vor. Intention dieser Studie war, eine FSE/UV-Kombinationsbehandlung an einem größeren Patientenkollektiv mit mittelschwerer bis schwerer Psoriasis zu untersuchen. PATIENTEN UND METHODIK: In dieser prospektiven, multizentrischen, nichtinterventionellen Studie wurden Daten von Patienten mit FSE/UV-Kombinationstherapie hinsichtlich der Wirksamkeit (PGA' PASI, DLQI, EQ-5D), Sicherheit und Dosierung über einen Zeitraum von zwölf Monaten erfasst und mit Daten einer retrospektiven Studie mit FSE-Monotherapie verglichen...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214307/krankheitsverlauf-medizinische-versorgung-und-lebensqualit%C3%A3-t-von-patienten-mit-kongenitalen-melanozyt%C3%A3-ren-n%C3%A3-vi-auswertung-des-deutschsprachigen-kmn-registers
#12
Maria Elisabeth Wramp, Anna Langenbruch, Matthias Augustin, Detlef Zillikens, Sven Krengel
HINTERGRUND: Kongenitale melanozytäre Nävi (KMN) bedeuten für Patienten und Familien eine psychologische Belastung und bergen zudem medizinische Risiken. Das 2005 gegründete deutschsprachige KMN-Register wurde nun einer Zwischenauswertung bezüglich des Krankheitsverlaufes, der medizinischen Versorgung und der Lebensqualität unterzogen. PATIENTEN UND METHODIK: 100 Patienten, die sich in den Jahren 2005 bis 2012 mit einem Erstmeldebogen registriert hatten, wurde im Rahmen einer prospektiven Kohortenstudie Anfang 2013 ein Folgemeldebogen zugesandt...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28214304/efficacy-and-safety-of-fumaric-acid-esters-in-combination-with-phototherapy-in-patients-with-moderate-to-severe-plaque-psoriasis-fast
#13
Peter Weisenseel, Kristian Reich, Wiebke Griemberg, Katharina Merten, Christine Gröschel, Natalie Nunez Gomez, Kirsi Taipale, Beate Bräu, Ina Zschocke
BACKGROUND: While treatment of patients with moderate-to-severe psoriasis using a combination of fumaric acid esters (FAE, Fumaderm(®) ) and phototherapy (UV) is common practice, there have been hardly any studies investigating this regimen. Available information is limited to data from a small pilot study. The objective of the present study was to evaluate FAE/UV combination therapy in a larger patient cohort with moderate-to-severe psoriasis. PATIENTS AND METHODS: In this prospective noninterventional multicenter study, data from patients treated with FAE/UV combination therapy was assessed with regard to efficacy (PGA' PASI, DLQI, EQ-5D), safety, and dosage over a twelve-month period...
February 2017: Journal der Deutschen Dermatologischen Gesellschaft, Journal of the German Society of Dermatology: JDDG
https://www.readbyqxmd.com/read/28203058/quality-of-life-assessment-in-patients-with-alopecia-areata-and-androgenetic-alopecia-in-the-people-s-republic-of-china
#14
Min Zhang, Nan Zhang
INTRODUCTION: In medical terms, alopecia is considered a relatively mild dermatological condition that nevertheless is a serious condition, but it causes major depression in many sufferers. Alopecia areata (AA) and androgenetic alopecia (AGA) are the main types of hair loss. This study assessed the quality of life (QoL) of Chinese patients with AA and AGA using the Dermatology Life Quality Index (DLQI) questionnaire. METHODS: A total of 178 AA and AGA patients were enrolled in this study, and DLQI was used to evaluate the QoL of the patients...
2017: Patient Preference and Adherence
https://www.readbyqxmd.com/read/28196270/open-label-study-of-etanercept-treatment-in-patients-with-moderate-to-severe-plaque-psoriasis-who-lost-a-satisfactory-response-to-adalimumab
#15
J Bagel, S Tyring, K C Rice, D H Collier, G Kricorian, J Chung, J Iles, B S Stolshek, A Kaliyaperumal, K A Papp
BACKGROUND: Some plaque psoriasis patients experience secondary failure of tumour necrosis factor inhibitor therapy. OBJECTIVES: To evaluate efficacy, safety, and patient-reported outcomes (PROs) with etanercept in patients with secondary adalimumab failure. METHODS: This phase 4, open-label, single-arm, estimation study (NCT01543204) enrolled patients on adalimumab who had achieved static physician global assessment (sPGA) score 0/1 (clear/almost clear)...
February 14, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28182255/fatigue-in-psoriasis-a-controlled-study
#16
I M Skoie, I Dalen, T Ternowitz, G Jonsson, I Kvivik, K Norheim, R Omdal
BACKGROUND: Fatigue is associated with various chronic inflammatory diseases, but few studies have focused on its occurrence in psoriasis. OBJECTIVES: To describe fatigue prevalence and degree among patients with chronic plaque psoriasis compared with age- and gender-matched healthy subjects, and to examine how fatigue is influenced by essential clinical and demographic factors. METHODS: In 84 patients and 84 healthy subjects, fatigue severity was assessed using three different generic fatigue instruments: the fatigue Visual Analogue Scale (fVAS), the Fatigue Severity Scale (FSS), and the Short Form 36 (SF-36) vitality scale...
February 9, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28161837/autologous-platelet-rich-plasma-prp-in-chronic-penile-lichen-sclerosus-the-impact-on-tissue-repair-and-patient-quality-of-life
#17
Francesco Casabona, Ilaria Gambelli, Federica Casabona, Pierluigi Santi, Gregorio Santori, Ilaria Baldelli
PURPOSE: Lichen sclerosus (LS) is a chronic inflammatory skin condition that frequently involves the anogenital region. Ongoing research is focused on finding more effective treatments for tissue repair and reducing symptoms. The aim of this study is to evaluate the effectiveness of platelet-rich plasma (PRP) local injections in penile LS. METHODS: Forty-five male patients affected by penile LS underwent injections of autologous PRP in the affected skin areas. Age at diagnosis and at first treatment, number of treatments, clinical conditions (phimosis, splitting, inflammation, synechiae, meatus stenosis), symptoms (pain, burning, itching), and functional impairment were considered...
April 2017: International Urology and Nephrology
https://www.readbyqxmd.com/read/28160338/h1-antihistamine-refractory-chronic-spontaneous-urticaria-it-s-worse-than-we-thought-first-results-of-the-multicenter-real-life-aware-study
#18
M Maurer, P Staubach, U Raap, G Richter-Huhn, A Bauer, F Ruëff, T Jakob, A S Yazdi, V Mahler, N Wagner, U Lippert, U Hillen, A Schwinn, M Pawlak, N Behnke, K Chaouche, N Chapman-Rothe
BACKGROUND: Most data on chronic spontaneous urticaria (CSU) originate from highly selected patient populations treated at specialized centres. Little is known about CSU patient characteristics and the burden of CSU in routine clinical practice. AWARE (A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation) is an ongoing global study designed to assess chronic urticaria in the real-life setting. OBJECTIVE: To describe the baseline characteristics of the first 1539 German AWARE patients with H1-antihistamine-refractory CSU...
February 4, 2017: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28153023/reliability-and-validity-of-the-chinese-version-of-the-autoimmune-bullous-disease-quality-of-life-abqol-questionnaire
#19
Baoqi Yang, Guo Chen, Qing Yang, Xiaoxiao Yan, Zhaoxia Zhang, Dédée F Murrell, Furen Zhang
BACKGROUND: The autoimmune bullous diseases quality of life (ABQOL) questionnaire was recently developed by an Australian group and has been validated in Australian and North American patient cohorts. It is a 17-item, multidimensional, self-administered English questionnaire. The study aimed to validate the Chinese version of the ABQOL questionnaire and evaluate the reliability in Chinese patients. METHODS: The Chinese version of the ABQOL questionnaire was produced by forward-backward translation and cross-cultural adaptation of the original English version...
February 2, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28148701/need-for-improvement-in-current-treatment-of-psoriatic-arthritis-study-of-an-outpatient-clinic-population
#20
Brigitte Michelsen, Andreas P Diamantopoulos, Hege Kilander Høiberg, Dag Magnar Soldal, Arthur Kavanaugh, Glenn Haugeberg
OBJECTIVE: To explore the burden of skin, joint, and entheses manifestations in a representative psoriatic arthritis (PsA) outpatient cohort in the biologic treatment era. METHODS: This was a cross-sectional study of 141 PsA outpatients fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria and examined between January 2013 and May 2014. Selected disease activity measures were explored including Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PASDAS), Disease Activity Score for 28 joints (DAS28), Simplified Disease Activity Index (SDAI), and Psoriasis Area Severity Index (PASI)...
February 1, 2017: Journal of Rheumatology
keyword
keyword
15510
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"